Over the last ten years everyone ran from the word embryonic, all the companies world wide abandon hESC's, the religious right wing made sure government limited funding, and nobody thought it safe territory, let alone any profit to be made with these cells. One company went against the grain and bought up all the embryonic stem cell ip worldwide. That company is BTX. As CEO Dr. West has said recombinent DNA was first banned in university labrotories throughout the US, including Harvard.
Biotime's hESC Progenitor product line PureStem® has over 200 patented cell types.
OpRegen is BTX subsidiary Cellcure's AMD product using retinal progenitors, and BTX sub AST are also using PureStem's neural progenitors for their OPC1 Spine regen product.
What's next for Biotime's 200+ PureStem product line?
Over the next few years BTX's family of subsidiaries will continue to IPO, introducing progenitor derived products for multi-billion dollar medical conditions such as osteoporosis, and heart disease.
Biotime's ip is deep with over seven specific cartilage progenitor lines....nose, ear, knee, sturnum, etc.
So to recap, Biotime does have a monopoly on hESC derived progenitors. PureStem® is the name of the product in which these 200+ lines exist.
And it is my opinion that as a result of their stem cell ip domination, BTX will likely become the 800lb gorilla within the next medical paradigm shift--regenerative medicine.
90% of stem cell companies in sector either got boughtout, went bankrupt, or like BTX are at record lows. My feeling is that things will start to heat up FINALLY this yea with many clinical trial results due from companies still standing such as CUR, Brainstorm(BSTM?), Mesoblast, and of course BTX's subsidiaries OncoCyte & AST.
Mesoblast from Australia just reported positive mid phase trials the other day btw.